邁普醫學(301033.SZ):可吸收再生氧化纖維素產品的三類醫療器械註冊證已獲批准
格隆匯8月23日丨邁普醫學(301033.SZ)公佈,近日,公司通過國家藥品監督管理局政務服務門户系統的信息發佈獲悉,公司申請的可吸收再生氧化纖維素產品的三類醫療器械註冊證已獲批准,相關批准證明文件尚待領取,關於該產品的具體情況如下:

可吸收再生氧化纖維素是專門針對神經外科手術止血需求所開發的高性能止血產品,該產品醫療器械註冊證的取得,豐富了公司的產品組合和應用領域,提高了公司的綜合競爭力和市場拓展能力,其產業化將有望打破我國神經外科可吸收止血產品的長期進口壟斷。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.